Trial · NCT07803068
The Impact of 12-week Ashwagandha Supplementation Induced by Resistance Training on Strength, Levels of Neurotrophic and Stress Response Proteins, Oxidative and Psychological Stress, and Cognitive Function in Physically Active Male Adults
NCT07803068, Not applicable, Recruiting, Gdansk University of Physical Education and Sport
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. The Impact of 12-week Ashwagandha Supplementation Induced by Resistance Training on Strength, Levels of Neurotrophic and Stress Response Proteins, Oxidative and Psychological Stress, and Cognitive Function in Physically Active Male Adults. Trials, record NCT07803068. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07803068
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
The Impact of 12-week Ashwagandha Supplementation Induced by Resistance Training on Strength, Levels of Neurotrophic and Stress Response Proteins, Oxidative and Psychological Stress, and Cognitive Function in Physically Active Male Adults
- NCT number
- NCT07803068
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Gdansk University of Physical Education and Sport
- Conditions
- Strength Training Adaptations, Stress, Sleep Quality, Cognitive Functions, Oxidative Stress, Inflammation
- Interventions
- Ashwagandha, Placebo, Resistance training
- First posted
- 2026-09-03
- Last updated
- 2026-09-03
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Maximal strength of upper lower limbs at 12 weeks. | Baseline and 12 weeks. | One-repetition maximum (1RM) in the bench press will be assessed using three attempts with progressively increased loads. Units: kilograms (kg) |
| Primary | Change from Baseline in cortisol levels at 12 weeks | Baseline to 12 weeks | Serum levels of cortisol will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions. Units: nmol/l |
| Primary | Change from Baseline in BDNF levels at 12 weeks | Baseline to 12 weeks | Serum levels of BDNF will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions. Units: pg/ml |
| Secondary | Change from Baseline in oxidative stress markers at 12 weeks. | Baseline to 12 weeks. | Spectrophotometric determination of lipid and protein peroxidation products in plasma will be conducted as markers of oxidative damage. |
| Secondary | Change from Baseline in visuospatial memory at 12 weeks | Baseline to 12 weeks | Participants will undergo neuropsychological Visual Patterns Test (VPT) administered by a licensed psychologist to evaluate visuospatial memory. Score will be evaluated as a total score of correctly remembered patterns. |
| Secondary | Change from Baseline in information processing efficiency at 12 weeks | Baseline to 12 weeks | Participants will undergo neuropsychological tests (Trail Making Test Part A and Trail Making Test Part B) administered by a licensed psychologist to evaluate information processing efficiency. Scores will be evaluated as completion time and number of mistakes. Shorter time and less mistakes mean better results. |
| Secondary | Change from Baseline in muscular endurance of upper limbs at 12 weeks. | Baseline and 12 weeks | Maximum number of repetitions at 75% 1RM in the bench press until failure will be performed. Units: number of repetitions |
| Secondary | Change from Baseline in testostrone levels at 12 weeks | Baseline to 12 weeks | Serum levels of testosterone will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions. Units: nmol/l |
| Secondary | Change from Baseline in subjective sleep quality at 12 weeks. | Baseline and 12 weeks | Participants will fill in a questionnaire Pittsburgh Sleep Quality Index (PSQI). Total scores will be shown on a scale from 0 to 21, with higher scores indicating worse outcomes. |
| Secondary | Change from Baseline in perceived stress at 12 weeks. | Baseline and 12 weeks. | Participants will fill in a questionnaire Perceived Stress Scale (PSS). Total scores will be shown on a scale from 0 to 40, with higher scores indicating worse outcomes. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Grid Pattern Span Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07803068
GET https://conductscience.org/api/trials/v1/NCT07803068/registered